This funding call aims to advance the development of cell secretome-based therapies, a promising alternative to traditional cell-based treatments. The secretome, defined as the collection of molecules secreted by cells, offers potential therapeutic benefits with fewer safety concerns. However, the lack of regulatory-approved therapies highlights existing challenges, including understanding the mode of action, standardizing manufacturing processes, and improving quality assurance.

The call invites proposals addressing these challenges and achieving safe, effective, and regulatory-approved secretome-based therapies for human use. Projects should focus on clinical studies, including Phase 1 and Phase 2 trials, while complying with regulatory requirements and ethical standards. Proposals should prioritize GMP-conform production, thorough characterizations of secretomes, and optimization of delivery strategies.

Preference will be given to therapies targeting widespread conditions or those imposing a significant burden on public health systems. Gender considerations should be addressed in both parent cell selection and therapeutic applications. Involvement of SMEs and the development of EU-focused exploitation strategies are encouraged.

Opening: 22-05-2025
Deadline(s): 18-09-2025

Data provided by Kooperationsstelle Wissenschaft

This funding opportunity represents a pre-agreed draft that has not yet been officially approved by the European Commission. The final, approved version is expected to be published in the first quarter of 2025. This draft is provided for informational purposes and may be used to preliminarily form consortia and develop project ideas, but it is offered without any guarantees or warranties.